Halozyme Therapeutics, Inc.
HALO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.28 | 0.23 | -1.50 | 0.00 |
| FCF Yield | 2.04% | 1.55% | 1.95% | 2.90% |
| EV / EBITDA | 34.04 | 33.76 | 54.46 | 36.59 |
| Quality | ||||
| ROIC | 8.33% | 8.50% | 5.68% | 7.01% |
| Gross Margin | 84.41% | 85.77% | 81.73% | 85.89% |
| Cash Conversion Ratio | 1.02 | 0.60 | 1.31 | 1.30 |
| Growth | ||||
| Revenue 3-Year CAGR | 16.76% | 15.07% | 15.43% | 15.43% |
| Free Cash Flow Growth | 78.88% | -35.96% | -12.62% | 54.06% |
| Safety | ||||
| Net Debt / EBITDA | 3.83 | 6.30 | 7.89 | 6.84 |
| Interest Coverage | 50.73 | 46.07 | 31.28 | 38.66 |
| Efficiency | ||||
| Inventory Turnover | 0.30 | 0.26 | 0.29 | 0.30 |
| Cash Conversion Cycle | 365.58 | 403.49 | 372.74 | 374.81 |